Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 01/05/2018

Debbie Rigby takes a look at the latest in research news Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT) A 24-week randomised controlled, comparative effectiveness trial comparing extended-release naltrexone, an opioid antagonist, and sublingual buprenorphine-naloxone, a partial opioid agonist has concluded these medicines indicated for opioid dependence are equally safe and

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Thank you’: How I saved a patient’s life with naloxone

You are right Adam it is absorbed orally and undergoes extensive first pass . Contraindicated in hepatic disease .

Michael Post

Patients back scope expansion

Ben, Hx and exam is a minimum 4 year medical degree. It takes many years of tertiary experience to learn…

Michael Post

CWH founders building a business for their ‘kids and grandkids’

“We need to move from a non-sophisticated business model to one with corporate governance. ... see that , I don't…

Ahmad Hawwari

CWH founders building a business for their ‘kids and grandkids’

Mmm doubt that , if CWH continue like this more influential people will have interest to lobby the government as…

Ahmad Hawwari

Research Roundup

Previous Setting the agenda

Next Mind-bending drugs and devices: can they make us smarter?

Shingles: managing a distressing skin condition

Impetigo: cause and treatment

Topical retinoids: versatile skin care ingredients

Ceramides: what are they and why are they important?

MENU

Previous Setting the agenda

Next Mind-bending drugs and devices: can they make us smarter?

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.